Assyro AI

Orange Book product · Brand (NDA)

VRAYLAR

CARIPRAZINE HYDROCHLORIDE

Brand (NDA)NDA 204370RX ABBVIE

At a glance

Sep 17, 2015

Approved

Brand (NDA)

Application

Not listed

TE code

18

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Sep 17, 2015

    10 yr 11 mo ago

  2. Today

  3. Patent 7943621 expires

    Listed drug substance patent expiration.

    Dec 16, 2028

    in 2 yr 6 mo

  4. Exclusivity ends · M-14

    New use / labeling-change exclusivity (3 years)

    Dec 18, 2028

    in 2 yr 6 mo

  5. Exclusivity ends · NPP

    New patient population exclusivity (3 years)

    Dec 18, 2028

    in 2 yr 6 mo

  6. Patent 7943621*PED expires

    Listed listed patent expiration.

    Jun 16, 2029

    in 3 yr

  7. Exclusivity ends · PED

    Pediatric exclusivity (adds 6 months)

    Jun 18, 2029

    in 3 yr 1 mo

  8. Exclusivity ends · PED

    Pediatric exclusivity (adds 6 months)

    Jun 18, 2029

    in 3 yr 1 mo

  9. Patent RE49110 expires

    Listed method-of-use patent (U-2545) expiration.

    Jul 16, 2029

    in 3 yr 1 mo

  10. Patent RE49110 expires

    Listed method-of-use patent (U-2543) expiration.

    Jul 16, 2029

    in 3 yr 1 mo

  11. Patent RE49110 expires

    Listed method-of-use patent (U-2544) expiration.

    Jul 16, 2029

    in 3 yr 1 mo

  12. Patent RE49110 expires

    Listed method-of-use patent (U-3503) expiration.

    Jul 16, 2029

    in 3 yr 1 mo

  13. Patent RE49302 expires

    Listed method-of-use patent (U-2543) expiration.

    Jul 16, 2029

    in 3 yr 1 mo

  14. Patent RE49302 expires

    Listed method-of-use patent (U-2545) expiration.

    Jul 16, 2029

    in 3 yr 1 mo

  15. Patent RE49302 expires

    Listed method-of-use patent (U-2544) expiration.

    Jul 16, 2029

    in 3 yr 1 mo

  16. Patent RE49302 expires

    Listed method-of-use patent (U-3503) expiration.

    Jul 16, 2029

    in 3 yr 1 mo

  17. Patent 7737142 expires

    Listed drug substance patent expiration.

    Sep 17, 2029

    in 3 yr 4 mo

  18. Patent 7737142 expires

    Listed drug substance patent expiration.

    Sep 17, 2029

    in 3 yr 4 mo

  19. Patent 7737142 expires

    Listed drug substance patent expiration.

    Sep 17, 2029

    in 3 yr 4 mo

  20. Patent 7737142 expires

    Listed drug substance patent expiration.

    Sep 17, 2029

    in 3 yr 4 mo

  21. Patent 7737142 expires

    Listed drug substance patent expiration.

    Sep 17, 2029

    in 3 yr 4 mo

  22. Patent RE49110*PED expires

    Listed listed patent expiration.

    Jan 16, 2030

    in 3 yr 8 mo

  23. Patent RE49302*PED expires

    Listed listed patent expiration.

    Jan 16, 2030

    in 3 yr 8 mo

  24. Patent 7737142*PED expires

    Listed listed patent expiration.

    Mar 17, 2030

    in 3 yr 10 mo

Pharmaceutical detail

Active ingredient

CARIPRAZINE HYDROCHLORIDE

Strength

EQ 3MG BASE

Dosage form

CAPSULE

Route

ORAL

TE code

Not listed

Application

NDA 204370

Product number

002

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (4)

  • M-14New use / labeling-change exclusivity (3 years)

    Dec 18, 2028

    in 2 yr 6 mo

  • NPPNew patient population exclusivity (3 years)

    Dec 18, 2028

    in 2 yr 6 mo

  • PEDPediatric exclusivity (adds 6 months)

    Jun 18, 2029

    in 3 yr 1 mo

  • PEDPediatric exclusivity (adds 6 months)

    Jun 18, 2029

    in 3 yr 1 mo

Listed patents (18)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7943621Dec 16, 2028in 2 yr 6 mo
SubstanceProduct
7943621*PEDJun 16, 2029in 3 yr
RE49110Jul 16, 2029in 3 yr 1 mo
U-2545
RE49110Jul 16, 2029in 3 yr 1 mo
U-2543
RE49110Jul 16, 2029in 3 yr 1 mo
U-2544
RE49110Jul 16, 2029in 3 yr 1 mo
U-3503
RE49302Jul 16, 2029in 3 yr 1 mo
U-2543
RE49302Jul 16, 2029in 3 yr 1 mo
U-2545
RE49302Jul 16, 2029in 3 yr 1 mo
U-2544
RE49302Jul 16, 2029in 3 yr 1 mo
U-3503
7737142Sep 17, 2029in 3 yr 4 mo
SubstanceProductU-2545
7737142Sep 17, 2029in 3 yr 4 mo
SubstanceProductU-2544
7737142Sep 17, 2029in 3 yr 4 mo
SubstanceProductU-1750
7737142Sep 17, 2029in 3 yr 4 mo
SubstanceProductU-3503
7737142Sep 17, 2029in 3 yr 4 mo
SubstanceProductU-2543
RE49110*PEDJan 16, 2030in 3 yr 8 mo
RE49302*PEDJan 16, 2030in 3 yr 8 mo
7737142*PEDMar 17, 2030in 3 yr 10 mo
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.